FDA Approves NINTEDANIB — Apotex Corp.

# FDA Approves Generic Version of Nintedanib, Enabling Significant Cost Savings for Pulmonary Fibrosis Patients Apotex Corp. has received FDA approval for a generic formulation of nintedanib esylate, a breakthrough therapy for idiopathic pulmonary fibrosis, which is expected to substantially reduce treatment costs and increase patient access to this critical medication. The approval of the oral generic version represents a major market shift in the antifibrotic drug segment, potentially disrupting pricing dynamics for the branded Ofev® and enabling broader adoption among underserved